Revance Therapeutics (NASDAQ:RVNC – Free Report) had its price objective lowered by Mizuho from $35.00 to $16.00 in a research report report published on Wednesday, Benzinga reports. Mizuho currently has a buy rating on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the company. BNP Paribas upgraded Revance Therapeutics from […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) shares rose 7% on Wednesday . The stock traded as high as $7.29 and last traded at $7.23. Approximately 173,042 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 1,630,483 shares. The stock had previously closed at $6.76. Wall Street […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price […]
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price decreased by Barclays from $40.00 to $35.00 in a research note published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the company. BNP Paribas upgraded Revance Therapeutics from an […]
First Republic Investment Management Inc. lowered its position in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 3.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,126 shares of the biopharmaceutical company’s stock after selling 1,684 shares during the period. First […]